Nothing Special   »   [go: up one dir, main page]

EE200100529A - Novel Polymorphic Forms of the Antidiabetic Agent: Method of Preparation and Pharmaceutical Compositions Containing Them - Google Patents

Novel Polymorphic Forms of the Antidiabetic Agent: Method of Preparation and Pharmaceutical Compositions Containing Them

Info

Publication number
EE200100529A
EE200100529A EEP200100529A EEP200100529A EE200100529A EE 200100529 A EE200100529 A EE 200100529A EE P200100529 A EEP200100529 A EE P200100529A EE P200100529 A EEP200100529 A EE P200100529A EE 200100529 A EE200100529 A EE 200100529A
Authority
EE
Estonia
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
polymorphic forms
antidiabetic agent
Prior art date
Application number
EEP200100529A
Other languages
Estonian (et)
Inventor
Reddy Gaddam Om
Kumar Potlapally Rajender
Sirisilla Raju
Krishnamurthi Vyas
Rao Dharmaraja Sreenivasa
Sarma Mamillapalli Ramabhadra
Original Assignee
Dr. Reddy's Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB1999/000681 external-priority patent/WO2000063191A1/en
Application filed by Dr. Reddy's Research Foundation filed Critical Dr. Reddy's Research Foundation
Publication of EE200100529A publication Critical patent/EE200100529A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/38—[b, e]-condensed with two six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
EEP200100529A 1999-04-16 2000-04-17 Novel Polymorphic Forms of the Antidiabetic Agent: Method of Preparation and Pharmaceutical Compositions Containing Them EE200100529A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB1999/000681 WO2000063191A1 (en) 1999-04-16 1999-04-16 Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
IN436MA1999 1999-04-19
PCT/IB2000/000470 WO2000063192A1 (en) 1999-04-16 2000-04-17 Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
EE200100529A true EE200100529A (en) 2002-12-16

Family

ID=26318745

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100529A EE200100529A (en) 1999-04-16 2000-04-17 Novel Polymorphic Forms of the Antidiabetic Agent: Method of Preparation and Pharmaceutical Compositions Containing Them

Country Status (17)

Country Link
EP (1) EP1171430A1 (en)
CN (1) CN1351597A (en)
AU (1) AU3831300A (en)
BG (1) BG106022A (en)
BR (1) BR0010683A (en)
CA (1) CA2370401A1 (en)
CZ (1) CZ20013711A3 (en)
EE (1) EE200100529A (en)
HR (1) HRP20010748A2 (en)
HU (1) HUP0200758A3 (en)
IL (1) IL145958A0 (en)
MX (1) MXPA01010472A (en)
NO (1) NO20015016L (en)
PL (1) PL351492A1 (en)
RU (1) RU2001130883A (en)
TR (1) TR200103851T2 (en)
WO (1) WO2000063192A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066135A1 (en) 2000-03-08 2001-09-13 Novo Nordisk A/S Lowering serum lipids
US6897199B2 (en) * 2001-02-05 2005-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds
JP4563675B2 (en) 2001-10-12 2010-10-13 ハイ・ポイント・ファーマスーティカルズ、エルエルシー Substituted piperidines and their use for the treatment of histamine H3 receptor related diseases
KR101018318B1 (en) 2001-12-21 2011-03-04 노보 노르디스크 에이/에스 Amide derivatives as gk activators
WO2003089425A1 (en) * 2002-04-19 2003-10-30 Faes Farma, S.A. Polymorph of acid 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-il]-1-piperidinyl]ethyl]-$g(a), $g(a)-dimethyl-benzeneacetic
BR0312023A (en) 2002-06-27 2005-03-22 Novo Nordisk As Compound, glucose kinase activating compound, method for preventing hypoglycemia, use of a compound, and pharmaceutical composition
WO2004101505A1 (en) 2003-05-14 2004-11-25 Novo Nordisk A/S Novel compounds for treatment of obesity
BRPI0414890A (en) 2003-09-30 2006-12-12 Novo Nordisk As compound, methods of retarding the progression of igt to type 2 diabetes, and type 2 diabetes to insulin-requiring diabetes, to treat obesity or prevent overweight, to regulate appetite, to induce satiety, to prevent weight gain. weight, increasing energy expenditure, and treating a disease or condition, pharmaceutical composition, and use of a compound
DE602004031455D1 (en) 2003-12-09 2011-03-31 Novo Nordisk As REGULATION OF FOOD PREFERENCE WITH GLP-1 AGONISTS
CN102516240A (en) 2004-01-06 2012-06-27 诺和诺德公司 Heteroaryl-ureas and their use as glucokinase activators
EP1758856A2 (en) 2004-05-04 2007-03-07 Novo Nordisk A/S Indole derivatives for the treatment of obesity
WO2005120492A1 (en) 2004-06-11 2005-12-22 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
JP4874989B2 (en) 2004-11-22 2012-02-15 ノヴォ ノルディスク アー／エス Soluble and stable insulin-containing formulation
KR101066882B1 (en) 2004-12-03 2011-09-26 트랜스테크 파르마, 인크. Heteroaromatic glucokinase activators
JP5121707B2 (en) 2005-07-04 2013-01-16 ハイ ポイント ファーマシューティカルズ，エルエルシー New medicine
EP1904467B1 (en) 2005-07-14 2013-05-01 Novo Nordisk A/S Urea glucokinase activators
ES2426345T3 (en) 2005-07-20 2013-10-22 Eli Lilly And Company Compound bound in 1-amino position
WO2007123581A1 (en) 2005-11-17 2007-11-01 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
MX2008011123A (en) 2006-03-28 2008-09-30 High Point Pharmaceuticals Llc Benzothiazoles having histamine h3 receptor activity.
DK2079732T3 (en) 2006-05-29 2012-01-23 High Point Pharmaceuticals Llc 3- (1,3-Benzodioxol-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates, and its use as histamine H3 receptor antagonists
ATE523497T1 (en) 2006-11-15 2011-09-15 High Point Pharmaceuticals Llc NEW 2-(2-HYDROXYPHENYL)BENZIMIDAZOLES SUITABLE FOR THE TREATMENT OF OBESITAS AND DIABETES
ES2377322T3 (en) 2006-11-15 2012-03-26 High Point Pharmaceuticals, Llc New 2- (2-hydroxyphenyl) benzothiadiazines useful for the treatment of obesity and diabetes
EP2099777B1 (en) 2007-01-11 2015-08-12 Novo Nordisk A/S Urea glucokinase activators
JP2010013472A (en) * 2009-09-09 2010-01-21 Faes Farma Sa POLYMORPH OF 4-[2-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOL-2-YL]-1-PIPERIDINYL] ETHYL-alpha,alpha-DIMETHYL BENZENOACETIC ACID
WO2011104378A1 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides for treatment of obesity
BR112012021231A2 (en) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh method for enhancing plant yield, plant, construct, use of a construct, method for producing a transgenic plant, collectable parts of a plant, products derived from a plant, use of a nucleic acid and method for producing a product
AU2011231503C1 (en) 2010-03-26 2016-03-03 Novo Nordisk A/S Novel glucagon analogues
WO2012104834A1 (en) 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
CN103596583B (en) 2011-03-28 2016-07-27 诺沃—诺迪斯克有限公司 Novel glucagon analogs
RU2017101333A (en) 2011-09-23 2018-12-19 Ново Нордиск А/С NEW GLUCAGON ANALOGUES
US20150004144A1 (en) 2011-12-02 2015-01-01 The General Hospital Corporation Differentiation into brown adipocytes
SI2986313T1 (en) 2013-04-18 2019-09-30 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
WO2015185640A1 (en) 2014-06-04 2015-12-10 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
EP3596107A1 (en) 2017-03-15 2020-01-22 Novo Nordisk A/S Bicyclic compounds capable of binding to melanocortin 4 receptor
WO2019219714A1 (en) 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
WO1997027191A1 (en) * 1996-06-19 1997-07-31 Dr. Reddy's Research Foundation Novel polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation
IN182496B (en) * 1996-02-20 1999-04-17 Reddy Research Foundation
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
FR2746099B1 (en) * 1996-03-13 1998-04-30 IMPROVED PROCESS FOR THE PREPARATION OF 3- (10-PHENOTHIAZYL) -PROPANOIC OR 3- (10-PHENOXAZYL) -PROPANOIC ACID DERIVATIVES
WO1999019313A1 (en) * 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
EP1051403A1 (en) * 1998-01-29 2000-11-15 Dr. Reddy's Research Foundation Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
JP2002507543A (en) * 1998-05-27 2002-03-12 ドクター・レディーズ・リサーチ・ファウンデーション Bicyclic compound, method for producing the same, and pharmaceutical composition containing them

Also Published As

Publication number Publication date
AU3831300A (en) 2000-11-02
BR0010683A (en) 2003-07-01
IL145958A0 (en) 2002-07-25
BG106022A (en) 2002-04-30
WO2000063192A1 (en) 2000-10-26
HUP0200758A3 (en) 2003-07-28
RU2001130883A (en) 2004-03-20
EP1171430A1 (en) 2002-01-16
CZ20013711A3 (en) 2002-07-17
HRP20010748A2 (en) 2003-02-28
MXPA01010472A (en) 2002-05-06
NO20015016L (en) 2001-12-11
CA2370401A1 (en) 2000-10-26
CN1351597A (en) 2002-05-29
NO20015016D0 (en) 2001-10-15
HUP0200758A2 (en) 2002-07-29
TR200103851T2 (en) 2002-04-22
PL351492A1 (en) 2003-04-22

Similar Documents

Publication Publication Date Title
EE200100529A (en) Novel Polymorphic Forms of the Antidiabetic Agent: Method of Preparation and Pharmaceutical Compositions Containing Them
EE04799B1 (en) Compounds useful as anti-inflammatory agents, methods of making these compounds, and pharmaceutical compositions containing them
EE200000791A (en) Novel acyl pseudopeptides, process for their preparation and pharmaceutical compositions containing them
EE05034B1 (en) Bicyclic heterocyclic compounds, pharmaceutical compositions containing them and methods for their preparation
EE04276B1 (en) Quinoline derivatives, their preparation and use as pharmaceuticals, and pharmaceutical compositions containing them
EE200000168A (en) Carboxamidothiazole derivatives, their preparation and pharmaceutical compositions containing them
EE200200138A (en) Quinolylpropylpiperidine Derivatives, their Preparation and Compositions Containing Them
EE200000707A (en) Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
EE200300046A (en) Azabicyclic compounds, their preparation and use as pharmaceuticals, and pharmaceutical compositions containing them
EE04613B1 (en) Carbohydrate-substituted 1,4-benzothiazepine-1,1-dioxide derivatives, process for their preparation, use of the compounds and medicament containing them
EE200200065A (en) 3-Aminopyrazole Derivatives, Their Preparation and Use as Anticancer Agents, and Pharmaceutical Composition Containing Them
EE200300080A (en) Polyarylcarboxamide Compounds, Their Preparation and Use as Lipid-lowering Agents, and Pharmaceutical Composition Containing Them
PT1066027E (en) PHARMACEUTICAL COMPOSITION OF TOPIRAMATO
EE200100259A (en) Pharmaceutical preparation of moxifloxacin
EE04015B1 (en) Substituted 2,4-Thiazolidinedione Derivatives, Methods of Preparation, and Pharmaceutical Compositions Containing Them
EE04717B1 (en) Indolylpiperidine Compounds, Method of Preparation, Composition and Use thereof
EE200300234A (en) Use of biphenylcarboxamide compounds as lipid-lowering agents, process for their preparation and pharmaceutical composition containing them
EE200200105A (en) Radiopharmaceuticals and Method of Preparation
HUP0201543A2 (en) Use of substituted imidazothiazoles as antidepressant agents, pharmaceutical compositions containing them and their preparation
EE200200022A (en) Aminothiazole derivatives, their preparation and pharmaceutical compositions containing them
EE03395B1 (en) Benzothiazolone derivatives, processes and intermediates used for their preparation, and pharmaceutical compositions containing them
EE200000421A1 (en) Novel pentasaccharides, processes for their preparation and pharmaceutical compositions containing them
EE200200292A (en) Substituted norbornylamino derivatives, their preparation and use as medicaments or diagnostic agents, and medicaments containing them
EE200100173A (en) 2-Phenylpyran-4-one derivatives, process for their preparation and use, use of intermediates and pharmaceutical composition
EE05192B1 (en) Trpamine derivatives and related compounds and pharmaceutical preparations containing them